Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $127.42 million. The enterprise value is -$25.24 million.
Important Dates
The last earnings date was Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 64.03 million shares outstanding. The number of shares has increased by 37.88% in one year.
| Current Share Class | 64.03M |
| Shares Outstanding | 64.03M |
| Shares Change (YoY) | +37.88% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 42.60% |
| Float | 27.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.48, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.48 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.77% and return on invested capital (ROIC) is -34.17%.
| Return on Equity (ROE) | -50.77% |
| Return on Assets (ROA) | -31.47% |
| Return on Invested Capital (ROIC) | -34.17% |
| Return on Capital Employed (ROCE) | -71.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.47M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.89% in the last 52 weeks. The beta is 0.87, so LRMR's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -71.89% |
| 50-Day Moving Average | 2.15 |
| 200-Day Moving Average | 4.82 |
| Relative Strength Index (RSI) | 46.57 |
| Average Volume (20 Days) | 1,458,646 |
Short Selling Information
The latest short interest is 9.83 million, so 15.36% of the outstanding shares have been sold short.
| Short Interest | 9.83M |
| Short Previous Month | 5.97M |
| Short % of Shares Out | 15.36% |
| Short % of Float | 36.21% |
| Short Ratio (days to cover) | 5.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -105.34M |
| Pretax Income | -58.34M |
| Net Income | -95.23M |
| EBITDA | -105.02M |
| EBIT | -105.34M |
| Earnings Per Share (EPS) | -$1.49 |
Full Income StatementBalance Sheet
The company has $157.53 million in cash and $4.87 million in debt, giving a net cash position of $152.66 million or $2.38 per share.
| Cash & Cash Equivalents | 157.53M |
| Total Debt | 4.87M |
| Net Cash | 152.66M |
| Net Cash Per Share | $2.38 |
| Equity (Book Value) | 144.27M |
| Book Value Per Share | 2.25 |
| Working Capital | 143.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$86.89 million and capital expenditures -$564,000, giving a free cash flow of -$87.45 million.
| Operating Cash Flow | -86.89M |
| Capital Expenditures | -564,000 |
| Free Cash Flow | -87.45M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |